Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2024 results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2024 results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2024 results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2024 results Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial in your area.
SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes
26.83
Semaglutide treatment reduces heart failure risks
22.69
Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial
21.22
In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
24.46
Trial Scorecard: SOUL
24.91
Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial–based analysis using NHANES (1988–2018) cycles
29.26
🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants
29.57
